Roth Capital Downgrades CollaGenex (CGPI) to Hold
More News related to CGPI
- CollaGenex Pharmaceuticals (CGPI) Reports Q4 EPS of $0.02
- Caxton Associates Discloses 6.1% Stake in CollaGenex (CGPI)
- Roth Capital Downgrades CollaGenex (CGPI) to Hold
- Wachovia Downgrades CollaGenex (CGPI) to Market Perform
- Rodman & Renshaw Downgrades CollaGenex (CGPI) to Market Perform
More News related to Downgrades
- Thomas Weisel Downgrades Vital Images (VTAL) to Marketweight
- Wells Fargo Downgrades Parkway Properties (PKY) to Underperform
- Piper Jaffray Downgrades Telvent Git S.A. (TLVT) to Neutral; Recommend Sidelines on Potentially Weaker Spain Business
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
Roth Capital downgrades CollaGenex (Nasdaq: CGPI) from Buy to Hold. Price target $16.60.
CollaGenex Pharmaceuticals, Inc. (CollaGenex) together with its subsidiaries, is a specialty pharmaceutical company focused on developing and marketing medical therapies to the dermatology market.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
